SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Research collaboration

23 Mar 2016 07:00

RNS Number : 9617S
Collagen Solutions PLC
23 March 2016
 

23 March 2016

Collagen Solutions Plc

(the "Company" or the "Group")

 

Collaboration with The Blond McIndoe Research Foundation

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces a research collaboration with Blond McIndoe Research Foundation ('BMRF'), a not for profit centre for regenerative medicine based at the Queen Victoria Hospital, East Grinstead, a world leading centre for the treatment of burns.

 

The pilot study will investigate the use of primary human skin cells used in formulation with Collagen Solutions products with a view to developing more effective treatments for burns, thereby reducing the burden and limitation of skin grafting. It is hoped that the combination of BMRF's experience in culturing cells specifically for treatment of burns and the use of high quality medical grade collagen will also enable the use of more effective application technologies for these types of injuries.

 

Dr Stewart White, Chief Executive Officer of Collagen Solutions said: "With over 13,000 UK hospital admissions* each year and 486,000** in the USA requiring medical attention, the care and treatment of burns presents a significant clinical need. We are extremely pleased to announce our collaboration with BMRF to work towards improved patient care. The experience the foundation has in the treatment of burns and wound care using the patient's own cells is truly world leading. Initially the project will confirm that our functional collagen formulations will provide a successful scaffold for these living cells. Based on successful outputs, we will then go on to jointly create a delivery process which can increase the ease of handling of these products by clinicians, alongside greater efficacy of the treatments themselves."

 

Maxine Smeaton, Chief Executive Officer of BMRF said: "We are delighted to announce this important partnership with Collagen Solutions. Working together we are utilising each other's experience and expertise in order to accelerate this vital work in cell delivery technologies. Collaborations of this nature are crucial to achieving high quality, impactful research that results in improved outcomes for people who have experienced serious, life-changing burn wounds."

 

*http://www.britishburnassociation.org/

**http://www.ameriburn.org/

 

Enquiries:

Collagen Solutions Plc

David Evans, Chairman

Tel: 07740 084 452

Stewart White, CEO

Tel: 0141 648 9100

Panmure Gordon & Co

Robert Naylor (Corporate Finance)

Maisie Atkinson (Corporate Broking)

Tel: 020 7886 2714Tel: 020 7886 2905

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Mike Wort

Mob: 07900 608 002

For Further information on the Blond McIndoe Research Foundation visit: www.blondmcindoe.org

 

Blond McIndoe Research Foundation

 

Maxine Smeaton, CEO

Tel: 01342 414 295

 

Mob: 07866 807720

 

Background to BMRF:

The Blond McIndoe Research Foundation (BMRF) is a not-for-profit centre for regenerative medicine. Our research supports people who have experienced life-changing damage or disfigurement as a result of serious burns, major soft tissue trauma or disease. Our programmes are focused on advancing wound healing techniques and technologies that aim to repair, restore and regenerate tissue and reduce debilitating scarring in order to improve function, form and comfort. Our co-location and strategic alliance with Clinicians at The Queen Victoria Hospital (QVH) in East Grinstead underpins our collective aspiration to deliver patient oriented innovations. 

 

We were founded in the name of surgical pioneer Sir Archibald McIndoe who treated many injured airmen during WW2, known as The Guinea Pig Club, and foresaw the need to advance the science of healing in order to benefit future generations. The pioneering spirit continued over the years leading to many significant developments such as ground breaking discoveries in graft rejection research which paved the way for the first microsurgical techniques such as toe to hand transplant. Some of our more recent innovations have included the development of sprayed skin cells for children's burns and new biomaterials designed to reconstruct tissue damaged by high energy trauma, such as blast injuries.

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAPGUGUWUPQGRP
Date   Source Headline
30th Aug 201711:21 amRNSResult of AGM
30th Aug 20177:00 amRNSAGM Statement
26th Jul 20177:00 amRNSPosting of Annual Report & notice of AGM
25th Jul 201711:36 amRNSDirector/PDMR Shareholding
25th Jul 20177:15 amRNSHardman Research: Transition to sustainable growth
13th Jul 201711:39 amRNSDirector/PDMR Shareholding
11th Jul 20177:00 amRNSFinal Results
7th Jul 20177:00 amRNSFirst patient enrolment in ChondroMimetic® study
19th Jun 20177:00 amRNSNotice of Results
13th Jun 20177:00 amRNSProvisional patent submitted
11th May 20177:15 amRNSHardman Research: Trading:earnings above forecasts
25th Apr 20177:00 amRNSTrading Update
24th Apr 20177:00 amRNSConsolidation of US R&D activities & Board change
10th Apr 20177:00 amRNSCollagen Based Spray Adhesive Poster Presented
3rd Apr 201711:22 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSAgreement signed with Smart Matrix Limited
31st Mar 20174:52 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSPericardium Divisional Patent in Australia
27th Mar 201712:39 pmRNSDirector/PDMR Shareholding
24th Mar 20179:26 amRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSAttending UK Investor Show
20th Mar 20178:56 amRNSIntroduces new online sales initiative in the US
15th Mar 20179:58 amRNSHolding(s) in Company
14th Mar 20173:28 pmRNSHolding(s) in Company
13th Mar 201711:52 amRNSHardman Research: Engineering cartilage repairs
13th Mar 20179:57 amRNSHolding(s) in Company
13th Mar 20177:05 amRNSHardman Research: Engineering cartilage repairs
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSAttending AAOS and ORS meetings in San Diego
8th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20174:08 pmRNSHolding(s) in Company
7th Mar 20171:01 pmRNSDirector/PDMR Shareholding
7th Mar 201711:19 amRNSHolding(s) in Company
7th Mar 20179:56 amRNSHolding(s) in Company
6th Mar 20172:24 pmRNSResult of General Meeting
20th Feb 20177:00 amRNSInvestor presentation
15th Feb 201711:29 amRNSGrant of Options
14th Feb 201711:24 amRNSHardman Research: Funding accelerated growth
14th Feb 20177:00 amRNSPlacing Open Offer and Debt Financing
7th Feb 20177:00 amRNSAttends MD&M West Conference in Anaheim
19th Jan 20177:00 amRNSNew Scientific Advisory Board appointments
13th Jan 20177:00 amRNSThird Medical Research Scotland Ph.D. Studentship
21st Dec 201612:06 pmRNSHardman Research: Foundations for strategic growth
19th Dec 20167:00 amRNSHalf-year Report
14th Dec 20167:00 amRNSPoster Presentation at TERMIS-AM
2nd Dec 20167:00 amRNSNotice of Results
13th Oct 20167:00 amRNSTrading Statement
3rd Oct 20167:00 amRNSChange of Adviser
15th Sep 20167:00 amRNSParticipation in major Horizon 2020 project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.